Prolonged neoadjuvant hormonal therapy enhances IL-17 A/STAT3-mediated inflammation in prostate cancer
Prolonged NHT enhances IL-17 A/IL-17RC-mediated inflammation in prostate cancer, potentially promoting tumor progression through STAT3 activation. Targeting the IL-17 A/STAT3 axis may offer therapeutic potential for advanced prostate cancer, although further validation is required before NHT can be incorporated into clinical guidelines.
Authors
- Hao Wang (ORCID: https://orcid.org/0000-0003-4807-3172)
- Dawei Xie (ORCID: https://orcid.org/0000-0002-5065-7305)
- Yifan Chu
- Weifeng He (ORCID: https://orcid.org/0000-0002-5302-4669)
- Siqi Wang (ORCID: https://orcid.org/0000-0002-4154-2266)
- Yirui Wei
- Jianwen Wang (ORCID: https://orcid.org/0000-0003-2227-1867)
- Pushen Yang
Institutions
- Hebei Yiling Hospital (CN)
- Beijing Hospital (CN)
- Beijing Chaoyang Emergency Medical Center (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1007/s12672-025-03945-7
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00